Thomas Swanson, MD
Neurology · Missoula, MTNPI 1376535575
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Supernus Pharmaceuticals, Inc. accounts for 72.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $4,602 and has fallen 93.5% since, to $300 in 2025.
Across 51 payments — averaging $212.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$8K
- Livanova USA, Inc.$1K
- Catalyst Pharmaceuticals, Inc.$625
- Jazz Pharmaceuticals Inc.$403
- UCB, Inc.$316
- Sunovion Pharmaceuticals Inc.$156
- plus $227 from 4 others
What the payments were for
- Speaking & faculty fees$5,74353%
- Travel & lodging$2,13420%
- Food & beverage$2,97527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 14 | $7,879 |
| Livanova USA, Inc. | 13 | $1,246 |
| Catalyst Pharmaceuticals, Inc. | 5 | $625 |
| Jazz Pharmaceuticals Inc. | 6 | $403 |
| UCB, Inc. | 5 | $316 |
| Sunovion Pharmaceuticals Inc. | 3 | $156 |
| Zogenix Inc. | 1 | $102 |
| Greenwich Biosciences, Inc. | 2 | $79 |
| AbbVie | 1 | $29 |
| SK Life Science, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OXTELLAR XR$7,648
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$743
- Fycompa$599
- Epidiolex$136
- VNS Therapy$132
- APTIOM$125
- Fintepla$102
How this compares
$10,851 in reported general payments places this provider in the 80th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 64 | $3,573 |
| Levetiracetam | 90 | $1,812 |
| Oxcarbazepine | 31 | $1,212 |
| Zonisamide | 38 | $1,156 |
| Primidone | 26 | $436 |
| Donepezil Hcl | 12 | $377 |
| Lamotrigine | 31 | $278 |
| Topiramate | 16 | $191 |
| Gabapentin | 19 | $117 |
| Tizanidine Hcl | 18 | $51 |
Paid to pharmacies, not to this prescriber.
Other neurology in Missoula
- Sarah KochMissoula$2K
- John SchaefferMissoula$1K
- Kyle SmithMissoula$1K
- Aakriti BertscheMissoula$421
- Michael YoungMissoula$44
- Lennard WilsonMissoula$0
- Ann CollierBillings$164K
- Dennis DietrichGreat Falls$140K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.